Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

October 27, 2010 06:30 ET | Source: Intellect Neurosciences, Inc.

Intellect Neurosciences, Inc. Obtains OX1 Phase 1b Draft Report Showing the Company's Lead Alzheimer's Candidate Was Safe and Well-Tolerated at All Dose Levels Tested

NEW YORK, Oct. 27, 2010 (GLOBE NEWSWIRE) -- Intellect Neurosciences, Inc. (OTCBB:ILNS), a biopharmaceutical company with an internal preclinical and clinical-stage pipeline and licenses with major...
October 13, 2010 10:24 ET | Source: Intellect Neurosciences, Inc.

Intellect Neurosciences Issues Letter to Shareholders

NEW YORK, Oct. 13, 2010 (GLOBE NEWSWIRE) -- Intellect Neurosciences, Inc. (OTCBB:ILNS), a biopharmaceutical company engaged in the discovery and development of disease-modifying therapeutic agents for...
October 05, 2010 08:00 ET | Source: Intellect Neurosciences, Inc.

Intellect Neurosciences, Inc. Obtains New Patent for Alzheimer Monoclonal Antibodies From the United States Patent and Trademark Office; Milestone Supports Company's Mission to Develop Innovative Disease Modifying Treatments for Alzheimer's Disease

NEW YORK, Oct. 5, 2010 (GLOBE NEWSWIRE) -- Intellect Neurosciences, Inc. (OTCBB:ILNS), a biopharmaceutical company with internal preclinical and clinical-stage pipelines, as well as multiple licenses...
September 20, 2010 08:48 ET | Source: Intellect Neurosciences, Inc.

Intellect Neurosciences CEO to Deliver Key Note Speech on the Development of Novel Alzheimer's Therapeutics at Medical Conference in Ireland

NEW YORK, Sept. 20, 2010 (GLOBE NEWSWIRE) -- Intellect Neurosciences, Inc. (OTCBB:ILNS), a biopharmaceutical company with both internal preclinical and clinical-stage pipelines, as well as multiple...
September 14, 2010 08:00 ET | Source: Intellect Neurosciences, Inc.

Intellect Neurosciences Launches New Website

NEW YORK, Sept. 14, 2010 (GLOBE NEWSWIRE) -- Intellect Neurosciences, Inc. (OTCBB:ILNS), a biopharmaceutical company engaged in the discovery and development of disease-modifying therapeutic agents...
September 08, 2010 08:30 ET | Source: Intellect Neurosciences, Inc.

Intellect Neurosciences Issues Letter to Shareholders

NEW YORK, Sept. 8, 2010 (GLOBE NEWSWIRE) -- Intellect Neurosciences, Inc. (OTCBB:ILNS), a biopharmaceutical company engaged in the discovery and development of disease-modifying therapeutic agents for...
September 07, 2010 08:00 ET | Source: Intellect Neurosciences, Inc.

Former Head of Discovery Translational Medicine at Wyeth Research and Pfizer Joins Intellect Neurosciences, Inc. as Key Consultant

NEW YORK, Sept. 7, 2010 (GLOBE NEWSWIRE) -- Intellect Neurosciences, Inc. (OTCBB:ILNS), a biopharmaceutical company with an internal preclinical and clinical-stage pipeline and licenses with major...
September 01, 2010 09:10 ET | Source: Intellect Neurosciences, Inc.

Intellect Neurosciences to Participate in Rodman & Renshaw 2010 Annual Global Investment Conference in New York on September 14, 2010

NEW YORK, Sept. 1, 2010 (GLOBE NEWSWIRE) -- Intellect Neurosciences, Inc. (OTCBB:ILNS), a biopharmaceutical company with an internal preclinical and clinical-stage pipeline and licenses with major...
August 19, 2010 15:13 ET | Source: Intellect Neurosciences, Inc.

Intellect Neurosciences, Inc. CEO Comments on Recent Events in the Development of Novel Alzheimer's Therapies

NEW YORK, Aug. 19, 2010 (GLOBE NEWSWIRE) -- Intellect Neurosciences, Inc. (OTCBB:ILNS), a biopharmaceutical company with an internal preclinical and clinical-stage pipeline and licenses with major...
August 18, 2010 08:08 ET | Source: Intellect Neurosciences, Inc.

Intellect Neurosciences, Inc. Locks Database for OX1 Phase 1b Clinical Trial

NEW YORK, Aug. 18, 2010 (GLOBE NEWSWIRE) -- Intellect Neurosciences, Inc. (OTCBB:ILNS) a biopharmaceutical company with an internal preclinical and clinical-stage pipeline and licenses with major...